Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
Conjugate:
alkaline phosphatase conjugate
Clone:
polyclonal
Application:
ELISA (d), IHC (p), WB
Citations:
33
biological source
goat
Quality Level
conjugate
alkaline phosphatase conjugate
antibody form
affinity isolated antibody
antibody product type
secondary antibodies
clone
polyclonal
form
buffered aqueous glycerol solution
species reactivity
human
technique(s)
direct ELISA: 1:30,000, immunohistochemistry (formalin-fixed, paraffin-embedded sections): 1:50, western blot: 1:30,000
shipped in
wet ice
storage temp.
2-8°C
target post-translational modification
unmodified
General description
Human IgGs are glycoprotein antibodies that contain two equivalent light chains and a pair of identical heavy chains. IgGs have four distinct isoforms, ranging from IgG1 to IgG4. These antibodies regulate immunological responses to allergy and pathogenic infections. IgGs have also been implicated in complement fixation and autoimmune disorders . Anti-Human IgG (γ-chain specific)-Alkaline Phosphatase antibody is specific for human IgG when tested against human IgA, IgG, IgM, and Bence Jones κ, and λ myeloma proteins.
Immunogen
Purified human IgG
Application
Anti-Human IgG (γ-chain specific)-Alkaline Phosphatase antibody is suitable for use in ELISA (at 1:2500 and 1:10,000 dilutions). The antibody can also be used for western blot (1:30,000) and immunohistochemistry (at 1:50 dilutions using formalin-fixed, paraffin-embedded sections).
Proteins harvested from E. coli cultures were run on SDS-page gel for western blot analysis using alkaline phosphatase conjugated goat anti-human IgG (chain specific) at a concentration of 1:10000 for the secondary. Membranes were developed using BCIP/NBT substrate (Sigma).
Proteins harvested from E. coli cultures were run on SDS-page gel for western blot analysis using alkaline phosphatase conjugated goat anti-human IgG (chain specific) at a concentration of 1:10000 for the secondary. IgG was detected in human serum by Elisa using alkaline phosphatase conjugated goat anti-human IgG (gamma-chain specific) diluted 1:5000 in 0.25% BSA/PBS. Assay was developed using p-nitrophenyl phosphate substrate (1mg/ml Sigma).
Physical form
Solution in 0.05 M Tris buffer, pH 8.0, containing 1 mM MgCl2, 10 mM glycine, 1% bovine serum albumin, 50% glycerol and 15 mM sodium azide
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Still not finding the right product?
Explore all of our products under Anti-Human IgG (γ-chain specific)−Alkaline Phosphatase antibody produced in goat
— or —
Try our Product Selector Tool to narrow your options
Storage Class
10 - Combustible liquids
wgk
WGK 2
flash_point_f
Not applicable
flash_point_c
Not applicable
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Related Content
Instructions
Ali Akyol et al.
Seizure, 16(3), 233-237 (2007-01-24)
Increased seropositivity for Toxoplasma gondii and Toxocara canis have been observed in epileptic patients. Our aim is to determine whether there is any relationship between these agents and epilepsy in our cryptogenic epilepsy group. We studied specific IgG antibodies against
D A Heim et al.
Molecular therapy : the journal of the American Society of Gene Therapy, 1(6), 533-544 (2000-08-10)
Host immune responses against foreign transgenes may be a major obstacle to successful gene therapy. To clarify the impact of an immune response to foreign transgene products on the survival of genetically modified cells, we studied the in vivo persistence
Rodrigo Lorenzi et al.
Annals of clinical biochemistry, 51(Pt 2), 248-257 (2013-08-29)
The soluble form of the receptor for advanced glycation end-products (sRAGE) has been studied in various diseases. It is not clear why sRAGE levels vary between studies, with controversial results. What also remains to be determined is whether receptor for